Table of Contents

Research Articles

• Research Articles

  A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma

  Lisa Mirabello, Roelof Koster, Branden S. Moriarity, Logan G. Spector, Paul S. Meltzer, Joy Gary, Mitchell J. Machiela, Nathan Pankratz, Orestis A. Panagiotou, David Largaespada, Zhaoming Wang, Julie M. Gastier-Foster, Richard Gorlick, Chand Khanna, Silvia Regina Caminada de Toledo, Antonio S. Petrilli, Ana Patiño-Garcia, Luis Sierrasesúmaga, Fernando Lecanda, Irene L. Andrulis, Jay S. Wunder, Nalan Gokgoz, Massimo Serra, Claudia Hattinger, Piero Picci, Katia Scotlandi, Adrienne M. Flanagan, Roberto Tirabosco, Maria Fernanda Amary, Dina Halai, Mandy L. Ballinger, David M. Thomas, Sean Davis, Donald A. Barkauskas, Neyssa Marina, Lee Helman, George M. Otto, Kelsie L. Becklin, Natalie K. Wolf, Madison T. Weg, Margaret Tucker, Sholom Wacholder, Joseph F. Fraumeni Jr, Neil E. Caporaso, Joseph F. Boland, Belynda D. Hicks, Aurelie Vogt, Laurie Burdett, Meredith Yeager, Robert N. Hoover, Stephen J. Chanock and Sharon A. Savage

  Cancer Discov September 1 2015 5 (9) 920-931; DOI:10.1158/2159-8290.CD-15-0125

  
  

  The risk variant rs7034162 in NFIB contributes to osteosarcoma metastasis susceptibility.

• Research Articles

  Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2^hi Macrophage–Derived VEGFA

  Allison S. Harney, Esther N. Arwert, David Entenberg, Yarong Wang, Peng Guo, Bin-Zhi Qian, Maja H. Oktay, Jeffrey W. Pollard, Joan G. Jones and John S. Condeelis

  Cancer Discov September 1 2015 5 (9) 932-943; DOI:10.1158/2159-8290.CD-15-0012

  
  

  Hyperpermeability of tumor vasculature is dynamic and restricted to the Tumor MicroEnvironment of Metastasis (TMEM).

• Research Articles

  HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance

  Kideok Jin, Sunju Park, Wei Wen Teo, Preethi Korangath, Sean Soonweng Cho, Takahiro Yoshida, Balázs Győrffy, Chirayu Pankaj Goswami, Harikrishna Nakshatri, Leigh-Ann Cruz, Weiqiang Zhou, Hongkai Ji, Ying Su, Muhammad Ekram, Zhengsheng Wu, Tao Zhu, Kornelia Polyak and Saraswati Sukumar

  Cancer Discov September 1 2015 5 (9) 944-959; DOI:10.1158/2159-8290.CD-15-0090

  
  

  HOXB7 is upregulated by MYC-mediated suppression of miR-196a and enhances expression of ER target genes in tamoxifen-resistant breast cancer cells.

• Research Articles

  Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

  Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok-Kin Wong and Pasi A. Jänne

  Cancer Discov September 1 2015 5 (9) 960-971; DOI:10.1158/2159-8290.CD-15-0063

  
  

  Acquired resistance to EGFR inhibitors can be prevented with dual EGFR and MEK inhibition, which results in prolonged ERK1/2 inhibition and increased apoptosis in EGFR-mutant NSCLC.

• Research Articles

  Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma

  Francesca Cottini, Teru Hideshima, Rikio Suzuki, Yu-Tzu Tai, Giampaolo Bianchini, Paul G. Richardson, Kenneth C. Anderson and Giovanni Tonon

  Cancer Discov September 1 2015 5 (9) 972-987; DOI:10.1158/2159-8290.CD-14-0943

  
  

  Upregulation of MYC in multiple myeloma cells drives DNA damage via replicative stress and ROS induction, and confers sensitivity to ATR inhibitors and small-molecule inducers of ROS.

• Research Articles

  Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy

  Gregory K. Behbehani, Nikolay Samusik, Zach B. Bjornson, Wendy J. Fantl, Bruno C. Medeiros and Garry P. Nolan

  Cancer Discov September 1 2015 5 (9) 988-1003; DOI:10.1158/2159-8290.CD-15-0298

  
  

  High-dimensional analysis of patient-derived AML cells using mass cytometry identifies changes in immunophenotypic patterns and cell-cycle kinetics that are predictive of AML subtype and chemotherapeutic response.